期刊
CURRENT OPINION IN IMMUNOLOGY
卷 53, 期 -, 页码 45-50出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2018.04.002
关键词
-
类别
资金
- NIAID grant [R01 AI117287]
- NAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN272201400008C]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI117287] Funding Source: NIH RePORTER
The development of a broadly protective or universal influenza virus vaccine is currently a public health priority worldwide. The vast majority of these efforts is exclusively focused on influenza A viruses. While influenza A viruses cause the majority of all influenza cases worldwide, influenza B viruses should not be ignored. Approximately 25% of all influenza cases are caused by influenza B viruses which circulate as two distinct B/Victoria/2/87-like and B/Yamagata/16/88-like lineages. In contrast to popular belief, influenza B cases frequently cause significant morbidity and mortality, especially in children. Similar to influenza A viruses, influenza B viruses drift antigenically and the influenza B components of current vaccines have to be reformulated almost on an annual basis. A broadly protective vaccine against influenza B viruses is therefore urgently needed. Here we review both broadly protective anti-influenza B antibodies as well as the sparse attempts to create a universal influenza B virus vaccine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据